University Of Pittsburgh
Often-discarded lymphatic fluid may guide precision treatment for head and neck cancer
Lymphatic fluid from surgical drains could offer important insights to guide treatment for certain patients with head and neck cancer, according to study results.
Low-value care can be dangerous to patients; researchers are working on solutions
Low-value care can result in significant harm and costs to patients, although interventions involving patient and clinician education could help reduce these services, an expert said.
Longer-duration CPR does not improve survival after in-hospital cardiac arrest
Odds for survival after an in-hospital cardiac arrest decline from 22% after 1 minute of CPR to less than 1% after 39 minutes, with similar odds observed for brain function, according to registry data.
‘Across state lines’: Radiation oncologist takes on ‘preindustrial era’ telehealth laws
Shannon MacDonald, MD, never thought returning a patient’s phone call constituted “practicing medicine.”
Lung ultrasonography ‘rapid, sensitive and safe’ in detecting acute chest syndrome
Using lung ultrasonography to identify acute chest syndrome in patients with sickle cell disease resulted in favorable diagnostic accuracy, sensitivity and specificity, according to results published in CHEST.
Patients with sickle cell disease using disease-modifying therapies more, but not enough
Nearly three-quarters of individuals with sickle cell disease are not using disease-modifying therapies in their treatment, according to a study published in JAMA Network Open.
Some younger women with early breast cancer may be able to omit adjuvant radiotherapy
Younger postmenopausal women who underwent treatment without radiotherapy for early-stage hormone receptor-positive breast cancer experienced low 5-year recurrence rates, according to results presented at San Antonio Breast Cancer Symposium.
Tucatinib regimen extends PFS in advanced HER2-positive breast cancer
The addition of tucatinib to ado-trastuzumab emtansine significantly improved PFS among patients with unresectable locally advanced or metastatic HER2-positive breast cancer, according to study findings.
Findings may help resolve ‘active debate’ about adjuvant radiotherapy for breast cancer
SAN ANTONIO — Treatment de-escalation may be possible for patients with breast cancer who respond well to neoadjuvant chemotherapy, according to randomized phase 3 study results presented at San Antonio Breast Cancer Symposium.
Datopotamab deruxtecan extends PFS vs. chemotherapy in advanced breast cancer
MADRID — Datopotamab deruxtecan extended PFS compared with chemotherapy for patients with previously treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer, according to study results presented at ESMO Congress.